Pathway and Network Approaches for Identification of Cancer Signature Markers from Omics Data

Jinlian Wang1,7, Yiming Zuo1,6, Yan-gao Man2, Itzhak Avital2, Alexander Stojsadovin2-3, Meng Liu4, Xiaowei Yang4, Rency S. Varghese1, Mahlet G Tadesse5, Habtom W Ressom1*

1. Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA;
2. Bon Secours Cancer Institute, Richmond VA, USA;
3. Division of Surgical Oncology, Walter Reed National Military Medical Center, Bethesda, MD, USA;
4. Department of Public Health School of Hunter College, City University of New York, NYC, USA;
5. Department of Mathematics and Statistics, Georgetown University, Washington DC, USA;
6. Department of Electrical and Computer Engineering, Virginia Polytechnic Institute and State University, Arlington, VA, USA;
7. Genetics and Genomics Science, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

*Corresponding author: Habtom W Ressom, PhD. Professor, Department of Oncology Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Room 175 Building D, 4000 Reservoir Road, NW, Washington, DC 20057. Email: hwr@georgetown.edu Telephone: (202) 687-2283 Telefax: (202) 687-0227.

© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.

Received: 2014.09.24; Accepted: 2014.11.14; Published: 2015.01.01

Abstract

The advancement of high throughput omic technologies during the past few years has made it possible to perform many complex assays in a much shorter time than the traditional approaches. The rapid accumulation and wide availability of omic data generated by these technologies offer great opportunities to unravel disease mechanisms, but also presents significant challenges to extract knowledge from such massive data and to evaluate the findings. To address these challenges, a number of pathway and network based approaches have been introduced. This review article evaluates these methods and discusses their application in cancer biomarker discovery using hepatocellular carcinoma (HCC) as an example.

Key words: Biological pathways, system biology, high-throughput omics data, cancer biomarker.

Introduction

A better understanding of disease associated with biomarkers could potentially start a new area for uncovering the mechanism of cancer progression, development and offer better targets for drug development [1]. Studies on single gene/protein/metabolite molecular signatures offer limited insight into the complex interplay among the molecules responsible for progression of complex diseases such as cancer. Thus, there is a shift toward the identification of a panel of genes that interact directly or indirectly in the form of pathway or complex network to evaluate their association to cancer [2,3]. This is accomplished through massive data derived by high throughput omic technologies such as next generation sequencing, microarray, and mass spectrometry. Although thousands of candidate biomarkers have been discovered by these technologies, few of them have been transferred into practical application in clinical setting and new drug production. The challenges lie in (1) high false positive rate of the candidate biomarkers identified from omics data; (2) Lack of attention on the study of the context of biomarkers who are interacting each other in the form of pathway or network associated with cancer; (3) Fragmental and incomplete information based on biomarkers identified from solely omics platform; (4) Lack of effective algorithms that allow integration of diverse omics data sources to simulate the biological pathway and networks. To meet these challenges, a number of pathway and network based approaches have been introduced. This review article evaluates the advantages and limitations of these methods.

The traditional approaches that individual and a panel of cancer biomarkers are selected by analytic
methods such as analysis of variance (ANOVA), Lasso, pairwise, information theory and support vector machine (SVM) do not explicitly consider interaction between genes, proteins and metabolites. Compared to traditional methods, pathway and network centric methods naturally provide a way to understand the underlying pathways and the interactions between individual signature markers and non-markers. With the large-scale generation and integration of genomic, transcriptomic, proteomic, and metabolomic data, pathway/network-based methods provide a more effective and accurate means for cancer biomarker discovery. Increasingly, pathway and network-based analyses are applied to omics data to gain more insight into the underlying biological function and processes, such as cell signaling and metabolic pathways as well as gene regulatory networks [4-6]. A number of pathway/network-based methods have also been used for improving the prediction of cancer outcome, providing novel hypotheses for pathways involved tumor progression [7], and exploring cancer associated biomarkers [8]. For example, Taylor et al. [9] combined gene expression data with physical protein-protein interaction data to identify subnetwork markers for the prognosis of breast cancer and lymphoma patients. Torkamani and Schork [10] used gene co-expression network to infer cancer-initiating genes in breast, colorectal cancer, and glioblastoma. Kim et al. applied the MAPIT (Multi Analyte Pathway Inference Tool) algorithm to identify prognostic network markers to predict GBM patient survival time using multi-analyte network markers discovered by integrating gene expression profile, epigenomic profile, and protein-protein interactome [11]. Goh et al. [12] built a human disease network (HDN) by linking hereditary disease that share a disease-causing gene recorded in Mendelian Inheritance in Man (OMIM) database. Although the functional connections in the HDN remain to be further demonstrated, it inspires us to systematically study the relationships among diseases by constructing a network. More detailed descriptions of relationships between human disease and network essential for understanding of human have been recently summarized in reviews [2, 12-14].

In this review, we provide some pathway and network centric computational approaches and their applications for biomarker discovery.

### Summary of pathways and networks centric approaches for cancer biomarker discovery

Availability of biomedical pathways and networks based on large-scale data gathering through diverse omics data sources offers new opportunities to explain the causality of relationships between biological entities and cancers [15]. As shown in Figure 1, the general steps of the biomarker discovery include the following: 1) Define precisely a well-framed, relevant clinical problem and focus the experimental design around appropriate study populations and samples; 2) Collect tissue samples or fluids from patients and suitable assays; 3) Acquire high-throughput data from the omics technologies; 4) Analyze the data using signal processing, statistical and machine learning methods to select relevant features from the data; 5) Integrate the pathway/network knowledge from databases such as KEGG, HMDB and Reactome mapping candidate biomarkers to the corresponding pathways or networks; 6) Evaluate biomarkers to estimate their diagnostic or prognostic capability and clinical validity using alternative technologies such as Westen blot, ELSA, and RT-PCR. In computational aspect, cross-validation and independent validation are the commonly used methods to evaluate the performance of a biomarkers. P-values, sensitivity, specificity and the area under receiver operating curves (AUC) are used as quantitative indicators of the performance of the methods [16]; 7) Use the biomarkers for clinical applications after reliable pre-clinical tests and validation of the markers in a large population.

### Statistics methods

Statistical methods test scientific theories when observations, processes or boundary conditions are subject to stochasticity. For examples, the classical t-test has been extensively used for testing differential gene expression in microarray data [35]. However, this kind of procedure relies on reasonable estimates of reproducibility or within-gene error, requiring a large number of replicated arrays. Thus, several methods for improving estimates of variability and statistical tests of differential expression have been proposed. For example, Significance Analysis of Microarrays (SAM) aimed to improve the unstable error estimation in the two-sample t-test by adding a variance stabilization factor which minimizes the variance variability across different intensity ranges [36, 37]. ANOVA model approach is widely used in multiple kinds of omic data. For example, it was used to model microarray data with the effects of array, condition, and condition-array interaction and then to fit the residuals with the effects of gene, gene-condition interaction, and gene-array interaction [38,39]. Also, it was applied to capture the effects of controlled groups, batches, condition, alias of experimental equipment, and condition-metabolite interaction separately on LC-MS data [40]. To improve the accuracy and sensitivity of analytic results, false discovery rate (FDR) [41] and its refinement, q-value, (q-value package, www.bioconductor.org) have been rapidly
adopted for genomic, proteomics and metabolic data analysis including the widely-used SAM, DAVID [42] and other approaches [36]. Another statistics method for biomarker discovery is linear discriminant analysis (LDA), one of the classical statistical classification techniques based on the multivariate normal distribution assumption, is quite robust and powerful to discover biomarker or pathways between omics data for many different applications despite the distributional assumption. Compared to LDA, quadratic discriminant analysis (QDA) requires more observations to estimate each variance-covariance matrix for each class [43]. In addition, logistic regression analysis has been successfully used to evaluate biomarker performance of prostate cancer with mRNA profiling [44]. Logistic regression (LR) model based on the regression fit on probabilistic odds between comparing conditions requires no specific distribution assumption (e.g. Gaussian distribution) but is often found to be less sensitive than other approaches [42,43].

**Graph theory based network and visualization**

The modeling fundamentals of graph theory are often used to describe the global topology, structure or the community of a complex system. It emphasizes on entities (e.g., genes, proteins, diseases, biological process) and the relations between them. The complexity of graphical modeling can be either simple only with nodes and edges or more complex where edges have weights, and nodes and edges can be of different types. Recent publications have applied graphical modeling in computational biology to study biological networks, enhance the ability to draw causal inferences from functional MRI experiments, support the early detection of disconnection and the modeling of pathology spread in neurodegenerative disease such as Alzheimer’s disease [45-49]. For example, in mammalian cells, Bleris et al. have had early success in characterizing the dynamics of key feed forward modules and motifs, helping to enable the circuit design of adaptive gene expression [50]. Using graph based approaches, Ma’ayan et al. model cellular machinery including genes, proteins and other subcellular compartments [51], in which the interactions between components are drawn as edge connections between the relevant nodes [51]. Gene expression data combined with network analysis can yield important information on how expression variation relates to differences between observed states [52]. As closely connected genes tend to be involved in similar functions, network annotation can complement clusters obtained via fold change analysis [7]. A standard systems-based approach to biomarker and drug target discovery consists of placing putative or known biomarkers in the context of a network of biological interactions, followed by different ‘guilt-by-association’ analyses [53].
### Table 1. Computational methods for biomarker discovery categorized by their application, exemplary tools and URLs.

| Approaches                  | Technique & Application Examples                                                                 | Exemplary Tools & URLs                                                                 |
|-----------------------------|---------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| Statistical analysis        | Hypothesis testing, random sampling, ANOVA. Detection of differentially expressed genes/proteins, genotypes, biomarker filtering/selection[24] | BRB: http://linus.nci.nih.gov/BRB-ArrayTools.html | **PAM**: http://www-stat.stanford.edu/~tibs/PAM/ |
| Pattern recognition         | Machine learning, Probabilistic, instance-based, kernel classification models                       | SAM: http://www-stat.stanford.edu/~tibs/SAM/                                                | **Weka**: http://weka.wikispaces.com/ |
| Graph/network theory        | Network topology analysis, network visualization and data integration, clustering, Genetic, regulatory, protein-protein, signaling network analysis, biomarker/target identification[29] | **BioNet**: http://www.fda.gov/ScienceResearch/BioinformaticsTools/ucm285284.htm | **Jung**: http://jung.sourceforge.net/ |
| Data visualization and imaging | Sequence and cluster visualization, interactive visualization, statistical analysis graphs. Data exploration, biomarker visualization, model explanation in vivo/in vitro imaging of molecules and cells[29] | ** STRING**: http://string-db.org | **Cytoscape**: http://www.biostateny.org/ |
| Natural language processing and information retrieval | Ontologies, text mining, information representation standards, information retrieval and extraction. Inference of functional associations from publications, automated annotation and characterization[32,33] | **Cytoscape**: http://www.biostateny.org | **Graphviz**: http://www.graphviz.org/ |
| Software development, Internet technologies | Data warehouses and distributed information systems, semantic Web tools, information retrieval, extraction and curation. | **Osprey**: http://biobdata.mshri.on.ca/osprey/servlet/Index | **IPA**: http://www.ingenuity.com/products/pathways_analysis.htm |
|                            | Biomarker discovery and validation platforms, data mining tools, search and reasoning engines[34] | **30mics**: http://30mics.cndm.tw | **GO**: http://www.geneontology.org/GO.tools.shtml |

The goal of visualization is to find patterns and structures that remain hidden in the raw unstructured datasets. Graph visualization is key to display directly the various relationships between entities (e.g., genes, proteins). Challenges of graph visualization lie in 1) the high false positive rate of incorporating heterogeneous multi-omic datasets; 2) Visual representation of the logical structure transformed from the raw data; 3) Graph manipulation and layout algorithm for representing the complicated relationships between biological entities. 4) Heterogeneous omic data from different level visualization needs more flexibility for layered representation. A number of commercial and free sourced graph visualization tools and platforms have been extensively developed. For example, Cytoscape [31], one of the free open source platforms providing biological network analysis and visualization with more than 172 registered plugins contributed by the community, is very versatile in network applications, such as network importing, network integrating, inference customization, literature mining, topological clustering, functional enrichment, network comparison, and programmatic access [54]. 3DScapeCS, a Cytoscape plugin providing three-dimensional, dynamic, parallel network visualization for Mass Spectrometry (MS) molecular network [55]. IPA [56], a commercial software tool for pathway analysis with omics data provides powerful graphical visualized pathways and networks overlaid by diseases, drugs and biological process etc. PathwayStudio provide abstractive graphical interface for users to analyze gene expression, protein interaction and metabolic data to analyze and explore the pathways and networks identified from data. STRING not only gives the graphical visualized protein interaction of both known and predicted but also quantifies each pair of proteins by their interaction types such as physical interaction and gene fusion etc. [57].

### Bayesian methods and its derivatives.

Bayesian methods allow informative priors so that prior knowledge or results of a previous model can be used to inform the current model. In cancer bioinformatics and systems biology, the primary application of Bayesian methods include Bayesian inference, Bayesian network, Naive Bayes classifier and Bayesian variable selection. Among these methods, Bayesian network is one of the most common modeling tools for pathway and network analysis [19]. Bayesian network is a form of directed statistical modeling designed to capture conditional dependencies between probabilistic events [58]. It consists of a dependency structure and local probability model also named probabilistic graph models which include Hierarchical Bayesian Networks (HBN), Probabilistic Boolean Networks (PBN), Hidden Markov Models (HMM), and Markov Logic Networks (MLN) [59-61]. The dependency structure specifies how the variables are related to each other by drawing directed edges between the variables without creating directed cycles. Each variable depends on a possibly set of other
variables, termed "parents." Compared with other pathway/network centric method, Bayesian network model is capable of integrating heterogeneous data, missing value and dependent relationships between variables [62].

In a Bayesian network model, probabilities define the relationship between the current node and its predecessor or parent in a graph [63]. The power of these methods lies in their ability to facilitate the reverse engineering of multiplex networks based on molecular expression, molecular activity and/or cell behavior data, serving as a precursor to synthetic modifications of existing molecular pathways [69,70]. Bayesian inference is one of the very important Bayesian methods widely used in cancer biomarker discovery, signaling pathway and network inference [65,66]. It has previously been applied to gene expression data for inference of gene regulatory networks [67,68], infer both protein signaling networks [69,70] and gene regulatory networks [71]. To incorporate an explicit time element, dynamic Bayesian Inference was proposed to interrogate dynamic signaling responses within a Bayesian framework, with existing signaling biology incorporated through an informative prior distribution on networks [66]. In addition, Bayesian variable selection aims at solving the problems of "large p, small n" existing in omic data set and using prior knowledge such as pathway and protein interaction to estimate the posterior probability by Markov Chain Monte Carlo (MCMC) also widely used to infer functional interactions in biochemical pathway, model the interactions between different functional modules of a biological network [72] and pathway based cancer biomarker discovery [73,74]. For example, Yang et al. [21] used a Bayesian network to construct HCC cell networks and identify functional modules and interactions between these modules. Stochastic simulation models offer an alternative, but they are hitherto associated with a major disadvantage: their likelihood functions cannot be calculated explicitly, and thus it is difficult to couple them to well-established statistical theory such as maximum likelihood and Bayesian statistics. A number of new methods, among them Approximate Bayesian Computing and Pattern-Oriented Modeling, bypass this limitation. The difference between Bayesian and frequentist inference lies in the following: 1) Bayesian inference provides answers conditional on the observed data and not based on the distribution of estimators or test statistics over imaginary samples not observed (Rossi et al., 2005, p. 4); 2) It includes uncertainty in the probability model, yielding more realistic predictions. 3) It safeguards against overfitting by integrating over model parameters. But the quality of the prior information directly impacts the performance of the Bayesian methods. Also, they are unable to account for feed-back regulation, a hallmark of signaling networks.

**Text mining**

With the growth of information in literature and biomedical databases, biological and clinical scientists need efficient means of handling and extracting diagnostic methods and prognostic terms and information from scientific literature. For this purpose, text mining that comprises the discovery and extraction of knowledge from free text to generate new hypotheses particularly relevant and helpful in biomedical research [14]. Text mining complements the reading of scientific literature by individual researchers, allows rapid access to information contained in large volumes of documents and increases the reproducibility of literature searches by enabling users to process all documents for a specific result. The primary application of text-mining in biomedical research roughly lies in three aspects: 1) Simple text-mining such as transforming textual information into database content and integrating with existing knowledge resources to suggest novel hypotheses; 2) Literature analysis including clustering and classification of entities or diseases; 3) Integrative biology for producing or testing hypotheses against knowledge bases.

Currently, text mining is being successfully applied to the identification of molecular causes of diseases using facts from databases and literature [75-77]. For example, text-mining has been used to suggest disease biomarkers from the scientific literature, and made on the basis of the assumption that two proteins are likely to interact with each other if they share a substantial amount of contextual information [78,79]. By defining a gene of interest, a network is constructed from all scientific publications related to the query-defined gene. The results can be browsed by navigating through the visualized network. CoPub makes use of lexical resources for genes, proteins, Gene Ontology labels, diseases, pathways, drugs and tissues to identify and statistically to qualify the significance of a specific term for a gene or a set of genes [80]. The results return a set of annotations for their genes of interest. Besides, text mining has been widely used in industrial large scale knowledge base for query genes, proteins, metabolic compounds and drugs functional analysis. To visualize knowledge contained in the scientific literature, software tools have been developed that provide improved integration of text-mining results with other data resources. For example, IPA (Ingenuity) [56], KEGG [81], Pathway Studio [82] and HPRD [83] use text-mining to integrate gene/protein-phenotype associations linking genes and protein variants to the diseases, toxic
effects and drug response to their knowledge databases.

Depending on the tasks researchers address, text-mining can achieve different objectives. This include primarily the following: 1) retrieval information from relevant documents; 2) Identification of entities such as genes, diseases, complex relationship between entities and diseases and interactions between proteins and genes [80]; 3) Deposit extracted information into database or used to support manual database curation efforts [15]; 4) Generation hypothesis [79] and test novel research questions [78]. The trend of text-mining technique is shifting from the analysis of only abstracts to the full text of papers, from the analysis of gene and protein-related information to the information about cells, tissues and whole organisms. The most prominent shift is to integrate information from the literature with data sets from other domains such as gene expression profiles [84], genome-wide association studies (GWASs), biochemistry and phenotype [84,85]. Text-mining is prone to only abstracts to the full text of papers, from the curation efforts [15] ; 4) Generation hypothesis [79]

The methods described in Sections A-E have proven useful for discovering biomarkers from high-throughput omic data, analyzing protein-protein, protein-DNA, and kinase-substrate interactions, as well as for genetic interactions among genes [102]. These efforts have yielded good results in cancer biomarker discovery, protein interaction and interaction between genotype and diseases [103]. However, current omic technologies provide only limited fragmented reality of the biological functions within cell or cancer mechanism. Separate analysis of the data generated from each of these technologies is limited to revealing only partial aberrant molecular changes, because the interaction of multiple molecules cannot be modeled by isolated analysis of genes, proteins or metabolites. Furthermore, limitations such as intrinsic high noise, incomplete data, small sample-size, bias have motivated the use of integrative omic analysis and use of prior biological knowledge and information bases, rather than as mere collections of single large-scale omic studies [14, 34, 104]. However, integration of multiple disparate data types remains a significant challenge in systems biology research. Most recently, attempts at integration of multiple high-throughput omics data have concentrated on capturing regulatory associations between genes and proteins by comparing expression patterns across multiple conditions [105-107], combining functional characterization and quantitative evidence extracted from different data sources of all levels of gene products, mRNA, proteins and metabolites, as well as their interaction [108-110]. Some previous works [81, 111-113] in integrative analysis utilize pathways in the

Integrative methods

Integration of data from multiple omic studies not only can help unravel the underlying molecular mechanism of carcinogenesis but also identify the signature of signaling pathway/networks characteristic for specific cancer types that can be used for diagnosis, prognosis and guidance for targeted therapy. The methods described in Sections A-E have proven useful for discovering biomarkers from high-throughput omic data, analyzing protein-protein, protein-DNA, and kinase-substrate interactions, as well as for genetic interactions among genes [102]. These efforts have yielded good results in cancer biomarker discovery, protein interaction and interaction between genotype and diseases [103]. However, current omic technologies provide only limited fragmented reality of the biological functions within cell or cancer mechanism. Separate analysis of the data generated from each of these technologies is limited to revealing only partial aberrant molecular changes, because the interaction of multiple molecules cannot be modeled by isolated analysis of genes, proteins or metabolites. Furthermore, limitations such as intrinsic high noise, incomplete data, small sample-size, bias have motivated the use of integrative omic analysis and use of prior biological knowledge and information bases, rather than as mere collections of single large-scale omic studies [14, 34, 104]. However, integration of multiple disparate data types remains a significant challenge in systems biology research. Most recently, attempts at integration of multiple high-throughput omics data have concentrated on capturing regulatory associations between genes and proteins by comparing expression patterns across multiple conditions [105-107], combining functional characterization and quantitative evidence extracted from different data sources of all levels of gene products, mRNA, proteins and metabolites, as well as their interaction [108-110]. Some previous works [81, 111-113] in integrative analysis utilize pathways in the
form of connected routes through a graph-based representation of the metabolic network [114]. Other approaches focus on the functional module of protein interaction network and analyze experimental data in the context of pathways using multiple source omics data [14,115,116]. We and others have developed advanced bioinformatics tools and algorithms to facilitate the integration of diverse data types [34, 110, 117-120].

Different biological types of data, such as sequences, protein structures and families, proteomics data, ontologies, gene expression and other experimental data sets show a growing complexity produced by numerous heterogeneous application areas. The integration of heterogeneous data is therefore becoming more and more important. In order to gain insights into the complexity and dynamics of biological systems, the information stored in these data repositories needs to be linked and combined in efficient ways.

Application of biomarker discovery in HCC

Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the third leading cause of cancer death in the world, with the five-year survival rate approaching 7% [33]. Treatments of HCC include surgical resection and transplantation, ablative and transarterial chemoembolization, and systemic chemotherapy. Even so, no existing systemic chemotherapy is effective for advanced HCC [121,122]. For example, Lovet et al. [123] reported that targeted therapy with sorafenib which inhibits multiple tyrosine kinase receptors (RAS/VEGFR) may prolong survival by about three months. However, due to the redundancy and compensation of the signaling network in HCC, a significant reorganization of the signaling network observed such as down regulation of tumor suppressors (p53 and CHK1 when XIAP silenced or p-RB when CDK6 silenced) and upregulation of tumor promoting proteins (ETS1 when XIAP silenced or p-CREB when CDK6 silenced) may confer the growth benefit for cancer cells [124]. This example suggests providing pathways and network information may improve the efficacy of systemic chemotherapy of HCC. Chang et al [125] partitioned the complex oncogenic signaling networks into basic units, or functional modules, of signaling activity (e.g., a protein phosphorylating another protein to activate its kinase activity) and demonstrated that gene expression signatures based on these modules can predict the effectiveness of pathway-specific therapeutics [125]. Except for surgical resection/transplantation of early stage HCC, the survival time is not significantly prolonged by any of these treatments. Added to pathway and network centric method making use of omics data with systematic chemotherapy will benefit the development of newer therapeutic targets for HCC treatment.

In recent years, computational methods for models take more and more important roles in the HCC investigations [114,126,127]. Some computer systems have also been developed. For example, Shannon et al. [128] developed a java based tool Gaggle by integrating diverse databases (e.g., KEGG, BioCyc, String) and software (e.g., Cytoscape, R ) to simultaneously explore the experimental data (e.g., mRNA and protein abundance, protein-protein and protein-DNA interactions), functional associations, metabolic pathways (KEGG) and Pubmed abstracts. Recently, Zheng et al [129] identified the molecular events underlying the development of HCV induced HCC by integrating gene expression profile and protein interaction data. To get the subnetworks, they refined the network by removing a network component if the number of nodes is smaller than five. They found four subnetworks called normal-cirrhosis, cirrhosis-dysplasia, dysplasia-early and early-advanced HCC networks. From each of the sub networks they identified functional modules and hub genes. By comparing the pathways in each sub networks, they observed changes of pathways and network activities. Their findings were validated by literature. Even though the types of omics data they used only include gene expression and protein interactions, they provide a way to study the changes of network activities by analysis of omic data. Zhang et al. used systemat-ical method including partial least squares, literature mining technique and with GeneGO Meta-Core to discover the biomarkers of HCC with gene expression as well as protein data. Based on these marker genes, they constructed down regulated and up regulated networks. In the former, they identified 10 up regulated hub genes (MAPK1, SPI, HDAC1, YY1, ABL1, PTK2, SMAD2, NCOA3; CDC25A and NCOA2). They identified 7 hub genes (FOS, ESR1, JUNB, EGFR, SOCS3; FOLH1 and IGF1) in the latter. Partial least squares were employed to construct a classifier with these biomarkers. They used five-fold cross-validation and two independent datasets to evaluate the performance of the classifier. Furthermore, they used experimental immunohistochemistry and western blot measurements to verify the marker genes predicted by the classifier. Their results show that the network-based approach facilitates biomarker identification and improves classification accuracy [130]. Hollywood et al [131] identified driver genes which are potent diagnosis markers and mechanism study of HCC using t-statistic map (TM) and transcriptome correlation map (TCM) approaches with integration.
of DNA copy number measured by genomics CGH array and gene expression. They found 50 driver genes with significant prognostic relevance to HCC key signaling pathways such as mTOR, AMPK, and EGFR. siRNA-mediated knockdown experiments was used to evaluate the functional significance of the 50 driver genes [131].

Even though collection of diverse omics data to analyze the relationships between HCC phenotype and biological entities within the cell has been proved powerful enough, such integration is still fragmentary, incomplete and inadequate to reflect the whole picture of the cancer information and development. The amount of omics data from genomics, proteomics, metabolomics and interactomics is increasing. In pace with the explosion of omics data, a number of open-access databases, containing comprehensive gene, protein interaction, biological pathway and network information, are being developed to provide biologists with valuable tools for analyzing the data from complex biological systems. These include IntAct, BioGRID, MINT, KEGG, PID, STRING and REACTOME etc. all of which provide very useful qualitative mappings of functional associations between key components in canonical pathways [14]. Table 2 summarizes primary data source and URLs specific to HCC.

Table 2. Data sources and URLs for HCC databases.

| Data sources              | URLs                                                      |
|---------------------------|-----------------------------------------------------------|
| EHCO[132]                 | http://ehco.iis.sinica.edu.tw/                            |
| Onco.HCC[133]             | http://oncodb.hbc.ibms.sinica.edu.tw/index.htm            |
| HCVpro[134]               | http://cbrc.kaust.edu.sa/hcvpro/                           |
| HCVdb[135]                | http://euhcvdb.ibcp.fr/euHCVdb/                            |
| Hepatitis Virus Database  | http://s2as02.genes.nig.ac.jp                             |
| (HVDB) [136]              |                                                           |
| Los Alamos National      | http://hcv.lanl.gov                                       |
| Laboratory in the United  |                                                           |
| States[137]               |                                                           |
| LiverAtlas[138]           | http://liveratlas.hupo.org.cn                             |
| dbHCCvar[139]             | http://GenetMed.fudan.edu.cn/dbHCCvar                     |

Limitations of omics based biomarker discovery

With wide applications of omics technique, more accurate and ubiquitous biomarkers have been identified, but only few have been brought to clinical setting and many have proved to be irreproducible [140]. One of the concerns is that biomarkers identified suffer from low diagnostic specificity and sensitivity which leads to current cancer biomarkers have not yet made a major impact in reducing cancer burden. For instance, serum alpha-fetoprotein (AFP) is the most widely used biomarkers for detecting and monitoring of HCC, but the false negative rate with AFP levels may be high as 40% for patients with early stage of HCC, for advances patients, the AFP levels remain small in 15%-30% of patients [141].

One of the important limitations is possible artifacts in conducting biological experiments such as instrument variability. Others include bias in sample collection and sample handling which lead to cohort differences. For example, Sreekumar et al. [142] reported sarcosine as a prostate cancer biomarker through metabolomics analysis. However, subsequent validation study done by Jentzmik et al. [143] concluded that the levels of sarcosine measured by GC-MS could not differentiate malignant from non-malignant tissue. Collestei et al. reported no statistically significant difference between prostate cancer and healthy controls in the sarcosine to creatinine ratios and that the levels of sarcosine were about 11.7% higher in the healthy controls [144]. Another important limitation relates to lack of computational methods that can extract knowledge from omic data involving substantial amount of noise, high dimensionality, missing values, etc.

Although the use of pathway and network-based approaches and the integration of prior biological knowledge with omic data are promising in addressing some of the computational challenges, they too have some limitations as outlined below:

- mRNA levels and DNA alterations may not accurately reflect the corresponding protein levels and fail to reveal changes in posttranscriptional protein modulation (e.g., phosphorylation, acetylation, methylation, ubiquitination, etc.) or protein degradation rates. Correlation of mRNA with its associated protein expression can be relatively low. The signaling network constructed using these approaches does not reflect the dynamic signal flow in a spatial relationship. Also, the genomic changes (mRNA level, SNP, CNV, methylation) ultimately affect protein expression, activation and inactivation, which, in turn, controls cellular behavior.

- Current proteomic technologies provide only limited coverage of the proteome and more sensitive technologies are needed to identify and quantitate low abundant proteins [145,146].

- Interpretation of pathway mapping results from the fact that pathway annotations currently take little consideration of tissue specificities of genes or proteins in the pathway. This limits the tissue and/or isoform specificity in pathway annotations. Thus, specific steps of a pathway may not be actually active in tissues/cells from which the omics data may be generated. In some cases, this may occur because protein isoforms or splice
variants have been annotated as a protein class or a canonical protein sequence, respectively, in the pathway while they may be expressed differentially in different tissues/cells.

- Because biological pathways are inherently complex and dynamic, pathway annotations in different pathway databases vary significantly in pathway models and in a number of other aspects, e.g., specific protein forms, dynamic complex formation, subcellular locations, and pathway cross talks.

Current computational methods thus need to provide a solution to these issues including revealing patterns within the data, modeling heterogeneity, profiling of disease classes and subclasses, producing a predictive of patients’ classification, etc.. Biomarker discovery is now changing research away from descriptive, descriptive and contrasting evidence for hypotheses, to include relevant work, to formulate hypotheses, to find support- ing and contradicting evidence for hypotheses, to integrate research results into a framework of whole biological systems and to support the translation of research results across domains and into clinical applications.

**Conclusion**

Early detection of cancer improves survival and enhances quality of life. An ideal marker would be one that can be measured easily and reliably using an assay with high sensitivity and specificity and undergo rigorous validation before they are introduced into routine clinical care. Currently, the treatment of most cancers is based on the tissue types and clinical stages. This approach is often ineffective due to the heterogeneity of the tumors. Pathway and network based method have taken more important role in analysis of high-throughput data. Pathway and network based methods provide a global and systematical way to explore the relationships between biomarkers and their interacting partners. Thus, future work is likely to focus on using pathway and network based methods for biomarker discovery.

It is our expectation that methods discussed above will become a component in a shared infrastructure of biomedicale resources that can be used by researchers to identify and to retrieve the most relevant work, to formulate hypotheses, to integrate research results into a framework of whole biological systems and to support the translation of research results across domains and into clinical applications.

**Acknowledgements**

This study was supported by NIH Grant R01CA143420 awarded to HWR.

**Competing Interests**

The authors have declared that no competing interest exists.

**References**

1. Li Y, Agarwal P. A pathway-based view of human diseases and disease relationships. PLoS One 2009;4 (2):e3436.
2. Altman TJ, Boone C, Churchill GA, Hengartner MO, Mackay TF, Stemple DL. The future of model organisms in human disease research. Nat Rev Genet 2011;12 (8):575-82.
3. Baranzini SE. The genetics of autoimmune diseases: a networked perspective. Curr Opin Immunol 2009;21 (6):596-605.
4. Ding Y, Chen M, Liu Z, Ding D, Ye Y, Zhang M, Kelly R, Guo L, Su Z, Harris SC, Qian F, Ge W, Fang H, Xu X, Tong W. abiNet-an integrated network analysis tool for genomics and biomarker discovery. BMC Genomics 2012;13:325.
5. Feng, M, Gao W, Wang R, Chen W, Man YG, Figg WD, Wang XW, Dimitrov DS, Ho M. Therapeutically targeting gliyican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci U S A 2013;110 (12):E1083-91.
6. Murray RS: Myth of the chronic fatigue syndrome. West J Med 1991;155 (1):68.
7. Chuang HY, Lee E, Liu YT, Lee D, Deerker T. Network-based classification of breast cancer metastasis. Mol Syst Biol 2007;3:140.
8. Patino WD, Mian OY, Kang JG, Matoba S, Bartlett LD, Holbrook B, Trout HH, Alizadeh AA, Patel AP. Integrating sample categories. BMC Res Notes 2013;6:109.
9. Liu DT, Linding R, Warde-Farley D, Liu Y, Pesquita C, Faria D, Bull S, Watson T, Morris Q, Wan LA. Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat Biotechnol 2009;27 (2):199-204.
10. Torkamani A, Schork NJ. Identification of rare cancer driver mutations by network reconstruction. Genome Res 2009;19 (9):1570-8.
11. Kim J, Gao L, Tan K. Multi-analyte network markers for tumor prognosis. PLoS One 2012;7 (12):e52973.
12. Goh KL, Cusick ME, Valle D, Childs B, Vital M, Barabasi AL. The human disease network database.
13. Loscalzo J, Barabasi AL. Systems biology and the future of medicine. Wiley Interdiscip Rev Syst Biol Med 2011;3 (6):619-27.
14. Wang J, Zhang Y, Marian C, Ressom HW. Identification of aberrant pathways and network activities from high-throughput data. Brief Bioinform 2012;13 (4):406-19.
15. Dowell KG, McAndrews-Hill MS, Hill DP, Drabkin HJ, Blake JA. Integrating text mining into the MCI biocuration workflow. Database (Oxford) 2009;2009:bap019.
16. Ghosh D, Poisson LM. “Omic”s data and levels of evidence for biomarker discovery. Genomics 2009;93 (1):13-6.
17. Kuan PF, Wang S, Zhou X, Chu H. A statistical framework for Illumina DNA methylation arrays. Bioinformatics 2010;26 (22):2849-55.
18. Vinayagam A, Stelzl U, Foulle R, Plassmann S, Zemmer M, Timm J, Assmus HE, Andrade-Navarro MA, Wanker EE. A directed protein interaction network for investigating intracellular signal transduction. Sci Signal 2011;4 (189):ra8.
19. Gevaert O, Van Vooren S, De Moor B. A framework for elucidating regulatory networks based on prior information and expression data. Ann N Y Acad Sci 2007;1115:240-8.
20. Kinouchi DC, Saez-Rodriguez J, Swatok J, Burke JM, Lauffenburger DA, Setzer PK. Creating and analyzing pathway and protein interaction compendia for modelling signal transduction networks. BMC Syst Biol 2012;6:29.
21. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, Reid LM, Minato H, Honda M, Kaneko S, Tang YZ, Wang XW, EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009;136 (3):1012-24.
22. Mitsos A, Melas IN, Morris MK, Saez-Rodriguez J, Lauffenburger DA, Alexopoulos LG. Non Linear Programming (NLP) formulation for quantitative modeling of protein signal transduction pathways. PLoS One 2012;7 (11):e50085.
23. Vineetha S, Chandra Shekara Bhat C, Idicula SM. MicroRNA-mRNA interaction network using TSK-type recurrent neural fuzzy network. Gene 2013;515 (2):285-90.
24. Ji J, Jing L, Jiang H, Wen Q, Whitin JC, Tian L, Cohen HJ, Ling X. Cloud-based solution to identify statistically significant MS peaks differentiating sample categories. BMC Res Notes 2013;6:109.
25. Patino WD, Mian OY, Kang JC, Matoba S, Bartlett LD, Holbrook B, Trout HH, 3rd, Kozloff L, Hwang PM. Circulating transcriptome reveals markers of ath- erosclerosis. Proc Natl Acad Sci U S A 2005;102 (9):3423-8.
26. West M, Blanchette C, Dressman H, Huang E, Ishisha S, Spang R, Zuan H, Olsen JA Jr., Marks JR, Nevin JS. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A 2001;98 (20):11462-7.
27. Nguyen DV, Rocke DM. Partial least squares proportional hazard regression for application to DNA microarray survival data. Bioinformatics 2002;18 (12):1625-32.
28. Li L, Darden TA, Weinberg CR, Levine AJ, Pedersen LG. Gene assessment and sample classification for gene expression data using a genetic algo- rithm/k-nearest neighbor method. Comb Chem High Throughput Screen 2001;4 (8):727-39.
39. Deschamps AM, Spinale FG. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res 2006;69 (3):666-76.

40. Jia P, Zhong L, Jiang W, Zhang W, Zhao Z. dmG2DAS: dense module searching for genome-wide association studies in protein-protein interaction networks. Bioinformatics 2011;27 (1):95-102.

41. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of molecular interaction networks. Genome Res 2003;13 (11):2498-504.

42. Al-Shahrour F, Minguez P, Tarraga J, Montaner D, Alloza E, Vaquerozias JM, Conde L, Blaschke C, Vera J, Dopazo J. BABELOMICS: a systems biology perspective in the functional annotation of genome-scale experiments. Nucleic Acids Res 2006;34 (Web Server issue):W472-6.

43. Miwa M, Ohta T, Rak R, Rowley A, Kell DB, Pyysalo S, Ananiadou S. A method for identifying and ranking the evidence for biochemical pathways by mining reactions from text. Bioinformatics 2013;29 (13):144-52.

44. Waters KM, Liu T, Quensenberry RD, Willer AR, Bandyopadhyay S, Kathmann LE, Weber TJ, Smith RD, Wiley HS, Thrall BD. Network analysis of epidermal growth factor signaling using integrated genomic, proteomic and phosphor- ylation data. PLoS One 2012;7 (5):e34515.

45. Jain N, Thatte J, Braciale T, Ley K, O'Connell M, Lee JK. Local-boosted-error test for identifying differentially expressed genes with a small number of replicated microarrays. Bioinformatics 2003;19 (15):1945-51.

46. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98 (9):5116-21.

47. Nacheva EP, Grace CD, Brazma A, Gershman K, Howard-Jones R, Rei L, Gale RE, Linch DC, Hils RK, Russell N, Burnett AK, Kottaridis PD. Does BCR/ABL1 positive acute myeloid leukaemia exist? Br J Haematol 2013;161 (1):41-51.

48. Wolfinger RD, Gibson G, Wolfinger ED, Bennett L, Hamadeh H, Bushel P, Afshari C, Paules RS. Assessing gene significance from DNA microarray expression data via mixed models. J Comput Biol 2001;8 (6):625-37.

49. Darvin K, Randolph A, Ovvalles S, Halade D, Breeding L, Richardson A, Espinoza SE. Plasma Protein Biomarkers of the Geriatric Syndrome of Frailty. J Gerontol A Biol Sci Med Sci.

50. Kerr MK, Churchill GA. Bootstrapping cluster analysis: assessing the reliability of conclusions from microarray experiments. Proc Natl Acad Sci U S A 2001;98 (16):8961-5.

51. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100 (16):9540-5.

52. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4 (1):44-57.

53. Soukop M, Lee JK. Developing optimal prediction models for cancer classification using gene expression data. J Bioinform Comput Biol 2004;1 (4):681-94.

54. Huang Y, Pepe MS, Feng Z. Logistic Regression Analysis with Standardized Marks. Ann Appl Stat 2013;7 (3).

55. Fattovich G, Scorfinelli T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127 (Suppl 1):S35-50.

56. Jumpong T, Huancheng Z, Feng H, Yi G, Xiaoqin Y, Zhengmao L, Hong Z, Jianying Z, Yin W, Yuanhangang H, Jianlin Z, Longhua S, Guolin H. Proteomic identification of C/EBP as a potential diagnostic factor in hepatocellular carcinoma. J Biosci 2011;6 (4):659-68.

57. Marra MR, Ortu R, Wilcox SK, Steele F, Schneider D, Jarvis TC, Baird GS, Bennett L. Genomics from literature context. PLoS Comput Biol 2009;5 (11):e1000754.

58. Elkam PL, Tufte MS, Trusko BE, Brown SH. BionProspecting: novel marker discovery obtained by mining the bible. BMC Bioinformatics 2009;10 (Suppl 25).

59. Frigeri R, Heupers B, van Beek P, Bouwmais M, van Schai, r D, de Vlegh J, Polman J, Alkema W. CoPult: a literature-based keyword enrichment tool for microarray data analysis. Nucleic Acids Res 2008;36 (Web Server issue):W406-10.

60. Schwartz JS, Gaugain C, Nacher JC, de Daruvar A, Kanehisa M. Observing metabolic functions at the genome scale. Genome Biol 2007;8 (6):R23.

61. Nikitin A, Egorov S, Daraselia N, Mazo I. Pathway studio—the analysis and visualization of molecular networks. Bioinformatics 2003;19 (16):2157-9.

62. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Bornschein J, Reimand J, Li Y, Dandekar T, Uh extreme J. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2013;41 (Database issue):D885-95.

63. Pérez-Irastorza C, Wijst M, Bork P, Andrade MA. G2D: a tool for mining genes associated with disease. BMC Genet 2005;6:45.

64. Pérez-Irastorza C, Bork P, Andrade MA. Association of genes to genetically inherited diseases using data mining. Nat Genet 2002;31 (5):316-9.

65. Blagosklonny MV, Pardee AB. Conceptual biology: unraveling the genes. Nature 2002;416 (6879):373.

66. van Haagen HJ, Ioen PA, Botelho Bova A, de Morree A, van Mulligen EM, Chichester C, Kors JA, de Dunning JT, van Ommen GJ, van der Maarel SM, Kern VM, More B, Schuemie M. Novel protein-protein interactions inferred from proteomics in a disease-free tissue context. PLoS One 2009;4 (4):e5794.

67. Frigeri R, Heupers B, van Beek P, Bouwmais M, van Schaik D, de Vlegh J, Polman J, Alkema W. CoPult: a literature-based keyword enrichment tool for microarray data analysis. Nucleic Acids Res 2008;36 (Web Server issue):W406-10.

68. Schwartz JS, Gaugain C, Nacher JC, de Daruvar A, Kanehisa M. Observing metabolic functions at the genome scale. Genome Biol 2007;8 (6):R23.

69. Nikitin A, Egorov S, Daraselia N, Mazo I. Pathway studio—the analysis and visualization of molecular networks. Bioinformatics 2003;19 (16):2157-9.

70. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, Telicherla D, Raju R, Shafreen B, Venugopal A, Balakrishnan L, Harimuthu A, Banerjee S, Somanathan DS, Sebastian A, Rani S, Ray S, Harys Kihore C, Kath S, Ahmed M, Kashyap MK, Mohomed R, Ramachandra YL, Krishna V, Rahiman BA, Moottan S, Rangasanthan P, Ramabadran S, Cherkidy R, Pandey A. Human Protein Reference Database—2009 update. Nucleic Acids Res 2009;37 (Database issue):D767-72.

71. Wang YJ, Tadesse MG, Ressom HW. A Bayesian network model for omics data integration. Proceedings of the 2012 IEEE International Workshop on Genomic Signal Processing and Statistics (GENISPS). Washington DC, 2012.

72. Cohen KB, Johnson HL, Verspoor K, Roeder C, Hunter LE. The structural and content aspects of abstracts versus bodies of full text journal articles are different. BMC Bioinformatics 2010;11:149.

73. Levi I, Volpe M, Coor I, L’Annunziata N, Emuna L, Ben-Aroya S. Reverse PCA, a Systematic Approach for Identifying Genes Important for the Physical Interaction between Protein Pairs. PLoS Genet 2013;9 (10):e1003838.

http://www.jcancer.org
87. Li T, Zhu S, Shuai L, Xu Y, Yin S, Bian Y, Wang Y, Zuo B, Wang B, Wang Z, Zhao S, Zhang L, Zhang J, Gao GF, Allain JP, Li C. Identification of common mammosphere with hepatitis C virus/GV virus-B chimeras. Hepatology 2013.
88. Whitehead NW, Neubauer DW, Masui O, Romachin AD, Siu KW, Yousef GM. Identification and validation of dysregulated metabolic pathways in metastatic renal cell carcinoma. Tumour Biol 2013.
89. Tang H, Wei P, Duelle EJ, Risch HA, Olson SH, Bueno-de-Mesquita HB, Galli-龈is S, Holmes MM, Petersen GM, Bracci PM, McGinnis MR, Neutra RM, Tjioenreda M, Rouault-Rout CA, Katsch R, Triepungsual D, Panico S, Sand M, Peeters PH, Khaw KT, Amos CI, Li D. Genes-environment interactions in obesity- and diabetes-associated pancreatic cancer: A GWAS data analysis. Cancer Epidemiol Biomarkers Prev 2013.
90. Koo CL, Liew MJ, Mohamed MS, Mohamed Saifee AH. A Review for Detecting Gene-Geene Interactions Using Machine Learning Methods in Genetic Epimediology. Biomed Res Int 2013;2013:323725.
91. Yang ZK. NetworkDowel. Methods Mol Biol 2010;690:197-222.
92. Zhang F. Kaufman HL, Dong Y, Drabier R. Recursive SVM biomarker selection for early detection of breast cancer in peripheral blood. BMC Med Genomics 2013;6 Suppl 1:S4.
93. Mattison HA, Stewart T, Zhang J. Applying bioinformatics to proteomics: is machine learning the answer to biomarker discovery for PD and MS? Mov Disorder 2012;27(1):1395-97.
94. Andreyev AY, Shen Z, Guan Z, Ryan A, Fahe Y, Subramanian S, Raetz CR, Briggs S, Dennis EA. Application of proteomic marker ensembles to subcellular organelle identification using unsupervised analysis. Mol Cell Proteomics 2010;9(2):388-402.
95. Chattopadhyay S, Bagchi P, Dutta D, Mukherjee A, Kobayashi N, Chawlasarkar M. Computational identification of post-translational modification sites and functional families reveals possible moonlighting role of rotavirus VP7. Bioinformatics 2010;14(10):448-51.
96. Crooks GE, Wolfe J, Brenner SE. Measurements of protein sequence-structure correlations. Proteins 2004;57(4):804-10.
97. Wang J, Yu Y, Zhao Y, Zhang D, Li J. Evaluation and integration of existing methods for computational prediction of allergens. BMC Bioinformatics 2013;14 Suppl 4:51.
98. Werfel J, Krause S, Bischof AG, Mannix RJ, Tobin H, Bar-Yam Y, Bellin RM, Ingber DE. How changes in extracellular matrix mechanics and gene expression variability might combine to drive cancer progression. PLoS One 2013;8(10):e76122.
99. Wang SH, Sung JJ, Chan FK, To KF, Ng SS, Wang XJ, Yu J, Wu WK. Genome-wide association and sequencing studies on colorectal cancer. Semin Cancer Biol 2013.
100. Han H. A novel profile biomarker diagnosis for mass spectral proteomics. Pan Asian Bioproc 2014:1340-51.
101. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Belda K, Hashimoto M, Watanabe G, Gabriel S, Friedelman SL, Kumada H, Llovet JM, Golub TR. Integrative transcriptome analysis reveals common molecular subclasses of hepatocellular carcinoma. Cancer Res 2009;69(18):7385-92.
102. Park SJ, Lee SY, Cho J, Kim TY, Lee JW, Park JH, Han MJ. Global physiological understanding and metabolic engineering of microorganisms based on omics methods for computational prediction of allergens. Bioinformation 2010;4 (10):448-51.
103. McDermott JE, Taylor RC, Yoon H, Heffron F. Bottlenecks and hubs in gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology 2012;56(5):1792-803.
104. McDermott JE, Taylor RC, Yoon H, Heffron F. Bottlenecks and hubs in gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology 2012;56(5):1792-803.
105. McDermott JE, Taylor RC, Yoon H, Heffron F. Bottlenecks and hubs in gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology 2012;56(5):1792-803.
106. McDermott JE, Taylor RC, Yoon H, Heffron F. Bottlenecks and hubs in gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology 2012;56(5):1792-803.
107. McDermott JE, Taylor RC, Yoon H, Heffron F. Bottlenecks and hubs in gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology 2012;56(5):1792-803.
108. McDermott JE, Taylor RC, Yoon H, Heffron F. Bottlenecks and hubs in gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology 2012;56(5):1792-803.
109. McDermott JE, Taylor RC, Yoon H, Heffron F. Bottlenecks and hubs in gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology 2012;56(5):1792-803.
110. McDermott JE, Taylor RC, Yoon H, Heffron F. Bottlenecks and hubs in gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology 2012;56(5):1792-803.
111. McDermott JE, Taylor RC, Yoon H, Heffron F. Bottlenecks and hubs in gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology 2012;56(5):1792-803.
141. Singhal A, Jayaraman M, Dhanasekaran DN, Kohli V. Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence. Crit Rev Oncol Hematol 2011;82 (2):116-40.

142. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehta R, Lonigro RJ, Li Y, Nyati MK, Absan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457 (7231):910-4.

143. Jentzmik F, Stephan C, Lein M, Miller K, Kamlage B, Bethan B, Kristiansen G, Jung K. Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol 2011;185 (2):706-11.

144. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehta R, Lonigro RJ, Li Y, Nyati MK, Absan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8.

145. Beger RD, Sun J, Schnackenberg LK. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol Appl Pharmacol 2010;243 (2):154-66.

146. Sanefuji K, Taketomi A, Iguchi T, Sugimachi K, Ikogami T, Yamashita Y, Gion T, Soejima Y, Shirabe K, Maehara Y. Significance of DNA polymerase delta catalytic subunit p125 induced by mutant p53 in the invasive potential of human hepatocellular carcinoma. Oncology 2010;79 (3-4):229-37.